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Abstract 
Background: Methylxanthines are natural and synthetic compounds found in many foods, drinks, pharmaceuticals, 
and cosmetics. Aside from caffeine, production of many methylxanthines is currently performed by chemical synthe-
sis. This process utilizes many chemicals, multiple reactions, and different reaction conditions, making it complicated, 
environmentally dissatisfactory, and expensive, especially for monomethylxanthines and paraxanthine. A microbial 
platform could provide an economical, environmentally friendly approach to produce these chemicals in large quan-
tities. The recently discovered genes in our laboratory from Pseudomonas putida, ndmA, ndmB, and ndmD, provide an 
excellent starting point for precisely engineering Escherichia coli with various gene combinations to produce specific 
high-value paraxanthine and 1-, 3-, and 7-methylxanthines from any of the economical feedstocks including caffeine, 
theobromine or theophylline. Here, we show the first example of direct conversion of theophylline to 3-methylxan-
thine by a metabolically engineered strain of E. coli.
Results: Here we report the construction of E. coli strains with ndmA and ndmD, capable of producing 3-methylxan-
thine from exogenously fed theophylline. The strains were engineered with various dosages of the ndmA and ndmD 
genes, screened, and the best strain was selected for large-scale conversion of theophylline to 3-methylxanthine. Strain 
pDdA grown in super broth was the most efficient strain; 15 mg/mL cells produced 135 mg/L (0.81 mM) 3-methylxan-
thine from 1 mM theophylline. An additional 21.6 mg/L (0.13 mM) 1-methylxanthine were also produced, attributed 
to slight activity of NdmA at the N3-position of theophylline. The 1- and 3-methylxanthine products were separated by 
preparative chromatography with less than 5 % loss during purification and were identical to commercially available 
standards. Purity of the isolated 3-methylxanthine was comparable to a commercially available standard, with no con-
taminant peaks as observed by liquid chromatography-mass spectrophotometry or nuclear magnetic resonance.
Conclusions: We were able to biologically produce and separate 100 mg of highly pure 3-methylxanthine from theo-
phylline (1,3-dimethylxanthine). The N-demethylation reaction was catalyzed by E. coli engineered with N-demethyl-
ase genes, ndmA and ndmD. This microbial conversion represents a first step to develop a new biological platform for 
the production of methylxanthines from economical feedstocks such as caffeine, theobromine, and theophylline.
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Background
Xanthine is a ubiquitous naturally occurring purine base. 
Other common naturally occurring xanthine derivatives 
include caffeine (1,3,7-trimethylxanthine), theobromine 
(3,7-dimethylxanthine), and theophylline (1,3-dimeth-
ylxanthine, TP), which are found in many foods, drinks, 
and pharmaceuticals [1–3]. Paraxanthine (1,7-dimeth-
ylxanthine) and 1-, 3-, and 7-methylxanthines are also 
naturally occurring xanthine derivatives, but are tran-
sient metabolites found at very low levels [1, 2, 4]. Several 
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xanthine derivatives have also been synthesized chemi-
cally for use in the medical industry [5]. These com-
pounds, natural and synthetic, have been shown to have 
various biomedical effects, with targets including adeno-
sine receptors [6, 7], phosphodiesterases [8, 9], calcium 
release channels [10–13], and GABAA receptors [13, 14].
For example, 3-methylxanthine (3MX) has been 
assessed as an adenosine antagonist [6] and produces the 
same maximal relaxation of guinea pig tracheal muscle 
as does TP [15]. Given that 3MX is a metabolite of TP 
in humans [16], TP itself may be a prodrug; thus there is 
an interest in directly testing 3MX as well. 3MX and TP 
are also used to examine conformational heterogeneity 
in RNA aptamers and riboswitches [17, 18]. 1-methylx-
anthine (1MX) is an essential human urinary metabolite 
of caffeine and TP [19–22] and exhibits similar activities 
to other naturally occurring methylxanthines. Unlike caf-
feine, TP, and theobromine, 3MX and 1MX do not occur 
naturally at high levels in plants. Instead, 3MX and 1MX 
are currently produced only by chemical methods, which 
are difficult due to the challenge of achieving selective 
alkylation of each of the nitrogen atoms [23–26].
Many purine alkaloids are traditionally produced 
via Traube synthesis, which uses the cyclization of 
4,5-diaminopyrimidines with formic acid, dithiofor-
mic acid, or other carboxylic acids [27, 28]. Imidazoles 
are also used for the production of purines [29]. Zavi-
alov et  al. developed a practical method describing the 
synthesis of 1- and 1,3- substituted xanthines by react-
ing an imidazole precursor with carbamates in the pres-
ence of suitable base [30]. The reaction was carried out 
under inert conditions using solvents such as tetrahy-
drofuran, bis(2-methoxyethyl) ether, and toluene. About 
seven steps of synthesis were needed to get the targeted 
methylxanthine. Allwood et  al. developed a highly effi-
cient synthesis route to N-functionalized derivatives of 
xanthine by orthogonal safety-catch protection strategy 
using cyclocondensation of aminoimidazole with methyl-
2-phenylthioethyl carbamates [31]. Liu et al. synthesized 
novel substituted xanthines by 46 routes [32]. In one of 
the routes, xanthine analogs containing substituents 
at the N1, N3, and N7 atoms were produced by treating 
1,3-dialkyl-5,6-diaminouracils with triethylorthoformate. 
Traditionally, synthetic methods for the production of 
purine alkaloids utilize many undesirable chemicals, sol-
vents, and harsh reaction conditions, and result in mul-
tiple reactions with undesired products; therefore, it is 
complicated and expensive (Fig.  1a). For synthesis of 
specific alkylxanthines, such as 3MX, additional depro-
tection steps are needed and the overall yield from start-
ing material such as an imidazole precursor is highly 
variable, i.e., 65–90  %. However, the exact yield of each 
specific methylxanthine is not clear. At each step of the 
reaction, the intermediate needs to be purified before the 
next step. Three different solvents reportedly give differ-
ent yields [30].
Caffeine and related methylxanthines are toxic to most 
bacteria and invertebrates [33, 34]. However, some bac-
teria, most of which are Pseudomonads, have evolved 
the ability to metabolize caffeine [35–42]. The bacterial 
strain Pseudomonas putida CBB5 degrades caffeine via 
sequential N-demethylation to theobromine (3,7-dimeth-
ylxanthine), 7-methylxanthine, and ultimately xanthine 
[38]. CBB5 can also N-demethylate TP to 1MX and 3MX, 
which are further N-demethylated to xanthine. This is the 
first bacterial strain reported to grow on and metabolize 
TP [38]. These same pathways for caffeine and TP metab-
olism have also been characterized genetically in Pseu-
domonas sp. CES [39].
The enzyme NdmA catalyzes the N1-demethylation of 
TP to 3MX. In addition, NdmA also converts caffeine 
to theobromine [43]. This enzyme is a Rieske (2Fe-2S) 
non-heme iron monooxygenase that requires a partner 
reductase, NdmD, to transfer electrons from NADH. 
The reaction requires one molecule of O2 per methyl 
group removed, resulting in the production of formal-
dehyde and water. We previously showed that the ndmA 
and ndmD genes are expressed partly in soluble form in 
Escherichia coli [43], and that a strain expressing both 
genes can be used to convert caffeine to theobromine 
[44].
Our broader interest is to generate a new, common 
platform for biocatalytic production of several high value 
methylxanthines via metabolically engineered E. coli 
(Fig.  1b) from cheaper feedstocks such as caffeine, TP 
and theobromine (see Additional file 1: Table S1 for rela-
tive value of each compound). There is a high-value dif-
ferential between TP and desired product, 3MX (Fig. 1b). 
Our initial focus has been to produce 3MX from TP 
using E. coli engineered with ndmA and ndmD. Biocat-
alytically-produced 3MX, besides reagent market as well 
as potential pharmaceutical effects [6], has commercial 
application as a nutraceutical (unpublished, personal 
communication between senior author and two differ-
ent nutraceutical companies). There are several suppli-
ers of synthetic 3MX as reagents worldwide [45], but no 
current suppliers of 3MX produced through biocatalytic 
means. The preferred substrate of the NdmA enzyme is 
TP, with a kcat/KM ratio for TP nearly double that of caf-
feine [43]. The present work is the first report on the bio-
catalytic production of 3MX. The genes ndmA and ndmD 
were introduced into E. coli at different gene dosages, and 
the resultant strains were screened for 3MX production. 
The optimum strain with the highest 3MX production 
was chosen for further study, including small-scale pro-
duction of 3MX to dispatch to clients. NdmA produced 
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1MX as a minor product as a result of non-specific 
N-demethylation at the N3-position. 1MX was not fully 
characterized since this is not the best method to pro-
duce this fine chemical. The biocatalytic approach used 
here operates at ambient temperature and pressure and is 
environmentally friendly. In contrast, chemical synthesis 
of methylxanthines uses several chemicals, multiple reac-
tions, and non-ambient reaction conditions (Fig. 1a).
Results and discussion
Initial screening of growth and 3MX production 
by metabolically engineered E. coli
All plasmids and strains used in this work are listed in 
Table  1, and plasmid maps are provided in Additional 
file 1: Figure S1. We first tested conversion of TP to 3MX 
using a strain of E. coli that contained plasmid pAD1 
[23]. Resting cells (OD600 = 2.5) converted approximately 
Fig. 1 Methylxanthine production schemes. a Example of generalized synthetic methods adapted from [30]. b Production of 3MX (major product) 
and 1MX (minor product) from TP by metabolically engineered E. coli containing the ndmA and ndmD genes. Prices per gram given below the 
compounds are based on the Sigma Aldrich Catalog for the highest lot available (Additional file 1: Table S1)
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0.3  mM TP to 3MX over 1  h, after which the reaction 
essentially stopped (Fig. 2). In order to increase activity, 
plasmids dAA, dDD, and dDA were added to the strain 
carrying pAD1, resulting in three new strains. These 
new strains allowed us to test the effect of different lev-
els of ndmA and ndmD copy numbers on 3MX produc-
tion (see Additional file  1: Table S2 for approximate 
gene copy numbers of each strain). Addition of ndmA 
only (strain pAD1dAA) had very little effect on activity 
(Fig. 2). Increasing the copy number of both genes (strain 
pAD1dDA) greatly increased the activity over strain 
pAD1dAA, with nearly complete conversion in 3 h. How-
ever, increasing the ndmD gene copy number only (strain 
pAD1dDD) resulted in complete conversion of TP within 
2 h (Fig. 2). Strain pAD1dDD, which contained the low-
est ndmA copy number, exhibited a slightly higher activ-
ity than did strain pAD1dDA, suggesting that plasmid 
pAD1 provided a sufficient ndmA gene dosage. These 
results also indicated that the reaction was limited by 
the amount of soluble NdmD produced inside the cells, 
since the activity increased with increasing ndmD copy 
number.
In the case of plasmid pAD1, the ndmD gene is sepa-
rated from the T7 promoter by approximately 1.1 kb of 
sequence containing the ndmA ribosomal binding site 
and gene, followed by a short synthetic ribosomal bind-
ing site of unknown strength just before the ndmD gene 
(Additional file 1: Figure S1). SDS-PAGE of strain pAD1 
(Additional file 1: Figure S2) showed a strong band of sol-
uble NdmA, but very little NdmD (soluble or insoluble). 
In contrast, strain pAD1dDD had very strong soluble 
Table 1 Plasmids and strains used in this study
a Strain pAD1 was originally named E. coli strain RMS1 in a previous publication [44]
Name Characteristics Source
Plasmids
 pAD1 AmpR, T7 promoter, ndmA, ndmD, rbsAD1, F1 origin [44]
 pET28-His-ndmD KanR, T7 promoter, ndmD, F1 origin [43]
 pACYCDuet-1 Expression vector, CmR, 2 T7 promoters, p15A origin Novagen
 dA pACYCDuet-1 with one copy of ndmA This study
 dA0 pACYCDuet-1 with one copy of ndmA and a second MCS This study
 dAA pACYCDuet-1 with two copies of ndmA This study
 dD0 pACYCDuet-1 with one copy of ndmD and a second MCS This study
 dDD pACYCDuet-1 with two copies of ndmD This study
 dDA pACYCDuet-1 with one copy of ndmD and on copy of ndmA This study
E. coli strains
 E. coli BL21(DE3) F− ompT hsdSB (rB
−mB
−) gal dcm (DE3) Invitrogen
 E. coli pAD1a BL21(DE3) pAD1 [44]
 E. coli pAD1dDD BL21(DE3) pAD1 dDD This study
 E. coli pAD1dDA BL21(DE3) pAD1 dDA This study
 E. coli pAD1dAA BL21(DE3) pAD1 dAA This study
 E. coli dDA BL21(DE3) dDA This study
 E. coli pHisD BL21(DE3) pET28-His-ndmD [43]
 E. coli pDdAA BL21(DE3) pET28-His-ndmD dAA This study
 E. coli pDdA BL21(DE3) pET28-His-ndmD dA This study
Fig. 2 Degradation of TP by metabolically engineered E. coli resting 
cells. Shaded triangle strain BL21(DE3) (negative control); Open circle 
strain pAD1; Shaded circle strain pAD1dAA; Open triangle strain dDA; 
Shaded square strain pAD1dDA; Open square strain pAD1dDD. Cells 
(OD600 = 2.5) were incubated with 1 mM TP in 50 mM KPi buffer at 
30 °C with 400 rpm shaking, and metabolites were quantified via 
HPLC
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and insoluble NdmD bands. Based on activity and elec-
trophoretic analysis, plasmid pAD1 clearly did not pro-
duce sufficient soluble intracellular NdmD. This was 
confirmed using resting cells (OD600 = 2.5) of an E. coli 
strain containing only plasmid dDA, which consumed 
0.8 mM TP over 300 min (Fig. 2). Plasmid dDA is based 
on the pACYCDuet-1 backbone, giving a plasmid (and 
gene) copy number approximately fourfold lower than 
that of pAD1. In spite of the lower overall gene dosage, 
activity was much higher in strain dDA than in strains 
pAD1 and pAD1dAA. Methods to increase expression 
of ndmD from plasmid pAD1 only could involve using a 
known strong ribosomal binding site and/or a second T7 
promoter between ndmA and ndmD.
In order to increase intracellular levels of NdmD, a plas-
mid containing the ndmD gene placed immediately down-
stream of the T7 promoter and ribosomal binding site in 
pET28a(+) [43] was used. Compatible plasmids contain-
ing one or two copies of ndmA (plasmids dA and dAA, 
respectively) were then added to a strain of E. coli harbor-
ing pET28-His-ndmD. This resulted in strains with a low 
(pDdA) or medium (pDdAA) ndmA gene dosage, based on 
estimated copy number and number of genes in each plas-
mid. The activity and protein expression levels of these two 
strains were then compared with strain pAD1dDD, which 
had the highest ndmA dosage of the three (Additional 
file  1: Table S2). Strains pDdA, pDdAA, and pAD1dDD 
grew to a similar OD600 in 100  mL Luria–Bertani broth 
(LB) (Additional file 1: Table S3) when gene expression was 
induced as described in the “Methods” section. SDS-PAGE 
revealed that soluble (active) protein expression is about 
the same for NdmA and NdmD among the three strains 
(Additional file 1: Figure S2). Each wet cell paste was used 
to test the conversion of TP to 3MX by resuspending in 
KPi buffer to a final cell concentration of 30  mg/mL and 
initial TP concentration of 4 mM. After 90 min of the reac-
tion time, TP was reduced 56, 51, and 43 % by suspensions 
of pDdA, pDdAA, and pAD1dDD, respectively. Approxi-
mately 84, 82, and 81  % of the consumed TP was con-
verted to 3MX in strains pDdA, pDdAA, and pAD1dDD, 
respectively, with the remaining TP forming 1MX (Addi-
tional file 1: Table S3). Based on these results, strain pDdA 
was chosen for further studies due to the highest yield of 
3MX from TP. Clearly, the additional gene dosage of ndmA 
(pDdAA) did not improve 3MX yield, relative to single 
gene dose (pDdA). Therefore, the activity of the cells was 
proven to be independent of the ndmA gene dosage and 
highly dependent on the ndmD gene dosage and expres-
sion in each E. coli strain.
Comparison of growth media
The effect of culture medium on cell growth and activ-
ity was also measured by growing strain pDdA in 
Luria–Bertani Lennox (LB) and super broth (SB) media. 
SB produced approximately 50 % more cells than did LB 
(Additional file  1: Table S4). Cells were resuspended to 
15  mg/mL, and the initial TP concentration in activity 
assays was lowered to 1 mM in order to achieve complete 
conversion, which would facilitate downstream purifica-
tion and product recovery. TP was completely consumed 
in SB-grown cells within 90 min (Fig. 3). After 2 h, nearly 
all of the TP was consumed in both reactions (Additional 
file 1: Table S4). 3MX yield from TP was 82–83 %, with 
an additional 12–13 % being 1MX. Because the cells are 
capable of performing both N1- and N3-demethylations 
on both TP and also 1- and 3MX, some small amount 
of xanthine was also formed from the monomethylxan-
thine products. These results demonstrate that the media 
composition had no significant effect on product ratio. 
Given the complete conversion of TP achieved in shorter 
time and 50 % more biocatalyst harvested from SB, this 
medium was chosen for the production of 3MX to supply 
clients.
Although yield of 3MX is high, minor production 
of 1MX decreases the overall yield of 3MX. The slight 
N3-demethylation of TP by NdmA to form 1MX is 
surprising and in contrast with our previous findings 
that NdmA is highly specific for the N1 methyl group 
of caffeine and TP [43]. We therefore tested the activ-
ity of strain pDdA on caffeine and observed a slight 
(<2  %) N3-demethylation activity to form paraxan-
thine (1,7-dimethylxanthine, data not shown). The 
enzyme in the previously reported work was expressed 
in E. coli BL21(DE3) with a C-terminal hexahistidine 
(His6) tag for facile purification and assayed in  vitro, 
Fig. 3 Production of methylxanthines from TP by strain pDdA grown 
in SB. 1 mM TP (open circle) was converted to 0.81 ± 0.002 mM 3MX 
(shaded circle) and 0.13 ± 0.002 1MX (open square) within 90 min by 
15 mg/mL of resting cells. Concentrations reported are means with 
standard deviations of triplicate results
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and produced only 3MX from TP. 1MX was shown to 
be produced from TP by the highly-specific N3-dem-
ethylase NdmB-His. The present study utilizes NdmA 
expressed in the same microbial chassis without the 
His6 tag, and the reaction is carried out in  vivo. It is 
unclear whether performing the reaction in vivo, elimi-
nation of the His6 tag from NdmA, enzyme expres-
sion level, and/or enzyme solubility [46] are involved 
in the change in site specificity. In our in vitro studies, 
the minimum amount of enzyme was used in order 
to determine the kinetics [43], and the paraxanthine 
and 1MX products may have been below the detec-
tion limit. However, the reduction in enzyme expres-
sion level (comparing strains pAD1 and dDA vs. strain 
pDdA) in this work did not result in a lower ration 
of products. Clearly, an in  vitro approach would not 
be economical, as it would require addition of exter-
nal NADH. It should be noted, however, that addition 
of a His6 tag has been implicated in changing sub-
strate specificity of the thioesterase I in E. coli due to 
a slight change in active site geometry [47]. The reason 
for the discrepancy between NdmA and NdmA-His6 
is currently under investigation. The original strain 
of P. putida CBB5 produced approximately twice as 
much 3MX as 1MX [38], however, the 1MX produc-
tion in this strain, besides slight specificity of NdmA 
at N3-position, can mostly be attributed to NdmB [43]. 
Future work to reduce the N3-demethylation activity of 
NdmA in vivo when expressed in E. coli should create 
a more efficient process for production of 3MX, while 
simultaneously simplifying downstream recovery of 
3MX.
Larger scale reaction, preparative chromatography, 
and purification of 3MX
The reaction conditions for conversion of TP to 3MX 
were optimized by evaluating different concentrations of 
cells (5, 10, 15, 30, and 60  mg wet cells/mL) and initial 
substrate concentration (1, 2, and 4  mM TP). It is clear 
from the data presented in Fig. 4 that a reaction contain-
ing 1 mM TP and 15 mg/mL resting cells provides linear 
conversion of TP to 3MX. At these reaction conditions, 
the product concentration and reaction volume suited 
the prep high pressure liquid chromatography (HPLC) 
column for complete product recovery.
Production of 3MX was scaled up by growing the pDdA 
strain in SB media in four 2.8 L Fernbach flasks, resulting 
in a total yield of 20  g wet cells. The cell yield was suf-
ficient to perform a 1.3 L reaction with an initial TP con-
centration of 1 mM at 15 mg/mL resting cell suspension. 
Initial analysis by HPLC showed complete consumption 
of TP after 2  h of reaction time with formation of 0.81 
and 0.13 mM 3MX and 1MX, respectively. The products 
were separated by preparative chromatography (Addi-
tional file  1: Figure S3). Resolution of 3MX (retention 
time of 116  min) and 1MX (retention time of 136  min) 
was sufficient to collect each of the two products sepa-
rately. The two products were crystallized through evap-
oration and freeze-drying, resulting in 106 mg 3MX and 
a minor amount of 1MX. Because the very small amount 
of 1MX produced could not be collected from the walls 
of the freeze dryer tray, 1MX was not further character-
ized. We are attempting to produce 1MX from TP via a 
metabolically engineered E. coli host containing ndmB 
and ndmD. The NdmB enzyme has been shown to be 
highly specific for N3-demethylation [43], and a purified 
NdmB-His6 produced only 1MX in vitro.
The theoretical amount of 3MX produced in the reac-
tion was 175 mg (~81 % mole to mole conversion from 
TP); however 36  % of the post-reaction mixture was 
used to optimize the preparative chromatographic sep-
aration. Therefore, a total of 111 mg 3MX (64 % of the 
post-reaction mixture) was loaded onto the column for 
purification and recovery. The resulting 106  mg pure 
3MX indicates very little loss during separation with a 
purification yield of 95.5  % after optimization of sepa-
ration in the prep column. Improving the selectivity of 
NdmA so that it only produces 3MX from TP would fur-
ther increase the yield.
The reaction conditions described here could produce 
135 mg/L 3MX. To our knowledge, this is the first report 
describing the non-transient microbial production of 
3MX. Until now, all microbial production of 3MX has 
been as an intermediate in the caffeine and TP catabolic 
pathways [38, 48]. Therefore, there are no values in the 
literature with which to compare this yield. However, 
there was adequate amount for further analytical work 
and supply of samples to our clients.
Because the ndm genes have only recently been dis-
covered [43, 46], previous attempts to produce meth-
ylxanthines through a biocatalytic route have focused 
primarily on metabolism and enzymology studies for 
conversion of caffeine to theobromine. Research has 
shown that addition of certain divalent metal ions, such 
as Co2+, Ni2+, Cu2+, and Zn2+ have a strong inhibitory 
effect on degradation of theobromine accumulated from 
caffeine in whole cells of P. putida [49, 50]. However, 
there are no known specific inhibitors to stop the reac-
tion at the desired, high-value methylxanthines such as 
paraxanthine and 1-, 3-, and 7-methylxanthine. Also, 
this approach would not be optimal for methylxanthine 
production, as the wild type P. putida strains (CBB5 and 
others) have lower growth rates and cannot produce the 
same amount of enzyme (hence, catalytic activity) as can 
E. coli expressing the recombinant ndm genes. Jin et  al. 
[51] cloned genes from the caffeine biosynthetic pathway 
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of coffee and tea into Saccharomyces cerevisiae. The 
resulting strain produced a very low level (0.38 mg/L) of 
caffeine when fed exogenous xanthosine. Without addi-
tion of xanthosine, no caffeine was detected. Besides the 
low production level, use of plant genes restricts the pos-
sible products to 7-methylxanthine, theobromine, and 
caffeine, which are the metabolites of the caffeine biosyn-
thetic pathway. Caffeine is mostly produced during the 
decaffeination of coffee beans [52, 53]. Theobromine and 
TP are mostly produced synthetically [54, 55], although 
extraction from plants is possible [56]. Thus, further 
strain optimization and protein engineering will be 
required before use of plant-based genes can be used in a 
microbial system to produce high value methylxanthines.
Analytical characterization of biologically produced 3MX
The purity of both 3MX and 1MX was analyzed by ana-
lytical HPLC using appropriate authentic standards. The 
retention time of the biologically produced products 
(Additional file  1: Figure S3) and authentic standards 
were identical. The High Resolution LC-MS spectrum of 
biologically produced and standard 3MX matched very 
well (Fig. 5) and corresponded to the published spectrum 
[57]. LC/MS was recorded on ESI positive mode; distinct 
M +  1 ion peak at 167.0569  m/z was observed both in 
the standard (Fig. 5a) and the biologically produced 3MX 
(Fig. 5b).
The 1H NMR spectrum of biologically produced and 
standard 3-methyl xanthine also matched very well 
Fig. 4 Effect of cell and substrate concentrations on 3MX production by E. coli pDdA. Resting cell assays were performed using 5 (open triangle), 10 
(open square), 15 (open triangle), 30 (open diamond), and 60 (open circle) mg/mL wet cells. TP concentrations were 1 mM (a), 2 mM (b), and 4 mM (c). 
Concentrations of TP (left), 3MX (middle), and 1MX (right) are shown as means with standard deviations of triplicate reactions
Page 8 of 12Algharrawi et al. Microb Cell Fact  (2015) 14:203 
Fig. 5 LC–MS spectra of 3MX samples. a Spectrum of 3MX standard purchased from Sigma–Aldrich. b 3MX produced in this work. Inset to b: Puri-
fied, crystallized 3MX produced in this work
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(Additional file 1: Figure S4). 1H NMR was recorded on 
a Bruker 500 MHz spectrophotomer using DMSO-d6 as 
solvent. Standard 3-methylxantine showed presence of 
peaks at δ 13.48 (s, 1H) and 11.07 (s, 1H) corresponding 
to –NH proton, and peaks at δ 8.01 and 3.3 correspond-
ing to –C = H (s, 1H) and –CH3 group (s, 3H). The bio-
logically produced 3MX also showed peaks at δ 13.48 (s, 
1H) and 11.07 (s, 1H) corresponding to –NH proton, and 
peaks at δ 8.0 and 3.3 corresponding to –C = H (s, 1H) 
and –CH3 group (s, 3H).
Conclusions
Our present work describes, for the first time, biocatalytic 
production of 3MX from TP with high yield. The process 
is carried out under ambient conditions in a single step 
using metabolically engineered E. coli. The larger vision 
of our work is to produce several high-value methylxan-
thines using specific combinations of ndm genes meta-
bolically engineered in E. coli while choosing the best 
feedstock to get the highest yield of the specific product. 
This represents a new biocatalytic platform for produc-
tion of methylxanthines using multiple cheap feedstocks 
and a common process of fermentation to yield biocata-
lyst, reaction conditions, and separation process.
Methods
Chemicals and reagents
TP, 1MX, 3MX, and xanthine were purchased from 
Sigma–Aldrich (St. Louis, MO). Luria–Bertani Lennox 
(LB) and Difco Select APS™ Super Broth (SB) dehydrated 
media were obtained from Becton–Dickinson and Com-
pany (Sparks, MD). Isopropyl β-D-thiogalactopyranoside 
(IPTG) was obtained from RPI Corp. (Mt. Prospect., 
IL). All PCR reactions were performed with Phusion HF 
polymerase from New England Biolabs (Ipswich, MA). 
Restriction enzymes and PCR reagents were also pur-
chased from New England Biolabs. PCR primers were 
ordered from Integrated DNA Technologies (Coralville, 
IA). HPLC-grade methanol (J.T. Baker, Phillipsberg, NJ) 
was used in all chromatographic studies.
Plasmid construction
All plasmids and strains used in this work are listed in 
Table  1. The pACYCDuet-1 vector backbone, which 
has a low-to-medium copy number of 10–12, was used 
for plasmids dAA, dA, dDD, and dDA. Plasmid dA was 
created by adding a single copy of ndmA in a manner 
that removed the second multiple cloning site. Plasmids 
pAD1 and pET28-His-ndmD contain the pET32a(+) and 
pET28a(+) vector backbones, respectively, which have a 
copy number of approximately 40. All genes are under 
the control of the strong T7 promoter for induction with 
IPTG. In the case of plasmid pAD1, the genes ndmA and 
ndmD are under the control of a single T7 promoter with 
a short synthetic ribosomal binding site between the two 
genes to promote translation of ndmD.
The ndmA gene was amplified by PCR from P. putida 
CBB5 genomic DNA (gDNA) with three sets of prim-
ers: ndmA-F-NcoI (5′-GCAAGGTCCATGGAGCAG 
GCGATCATCAATGATGA-3′) and ndmA-R-KpnI 
(5′-CCTCCGGGTACCTTATATGTAGCTCCTATCG 
CTT-3′) produced insert 1, ndmA-F-NcoI and ndmA-
R-BamHI (5′-CCTCCGGGATCCTTATATGTAGCTCC 
TATCGCTT-3′) produced insert 2, and ndmA-F-NdeI 
(5′-GCACGGCATATGGAGCAGGCGATCATCAATG 
ATGA-3′) and ndmA-R-KpnI produced insert 3. Insert 1 
was cloned into the pACYCDuet-1 plasmid at the NcoI 
and KpnI sites, resulting in plasmid dA. This plasmid 
contained only one copy of ndmA controlled by the T7 
promoter. Insert 2 was also cloned into the pACYCDuet-1 
plasmid using the NcoI and BamHI sites, resulting in plas-
mid dA0. Plasmid dA0 contained one copy of ndmA and 
a second, empty multiple cloning site. Insert 3 was cloned 
into the second multiple cloning site of plasmid dA0 at 
the NdeI and KpnI sites, resulting in plasmid dAA.
In a similar fashion, the ndmD gene was also ampli-
fied from P. putida CBB5 gDNA by PCR using two sets of 
primers: ndmD-F-NcoI (5′-GTGAGATCCATGGACAA 
ACTTGACGTCAACCAGTGG-3′) and ndmD-R-BamHI 
(5′-GGGACGGGGATCCTCACAGATCGAGAACG 
ATTTTTTTGGA-3′) produced insert 4, and ndmD-F-
NdeI (5′-GTGAGATCATATGAACAAACTTGACGTCA 
ACCAGTGG-3′) and ndmD-R-KpnI (5′-GGGACGGGG 
TACCTCACAGATCGAGAACGATTTTTTTGGA-3′) 
produced insert 5. Insert 4 was cloned into the pACYC-
Duet-1 plasmid at the NcoI and BamHI sites, resulting in 
plasmid dD0, which contained one copy of ndmD and a 
second, empty multiple cloning site. Insert 5 was cloned 
into the empty multiple cloning site at the NdeI and KpnI 
sites of dD0, resulting in plasmid dDD. Insert 3 (con-
taining ndmA) was also cloned into the NdeI and KpnI 
sites of dD0, yielding plasmid dDA. DNA sequencing of 
all plasmids confirmed that PCR amplification and clon-
ing procedures did not introduce any mutations into the 
gene sequences.
Strain construction
E. coli BL21(DE3) is the parent strain for all bacterial 
strains used. A list of all strains in this study is given 
in Table  1. Plasmids dDD, dDA, and dAA were trans-
formed into strain pAD1, which already contained plas-
mid pAD1 [23], yielding strains pAD1dDD, pAD1dDA, 
and pAD1dAA, respectively. Plasmids dAA and dA were 
transformed into strain pHisD, which already contained 
pET28-His-ndmD [43], resulting in strains pDdAA and 
pDdA, respectively. Transformants were recovered on LB 
Page 10 of 12Algharrawi et al. Microb Cell Fact  (2015) 14:203 
agar containing appropriate antibiotics at the following 
levels: 34 μg/mL chloramphenicol, 100 μg/mL ampicillin 
and 30 μg/mL kanamycin.
Cell growth and protein expression
E. coli strains were grown in SB or LB medium with appro-
priate antibiotic at 37 °C with shaking at 250 rpm. Concen-
tration of antibiotic used was 34, 30, and 100  µg/mL for 
chloramphenicol, kanamycin, and ampicillin respectively. 
Cell density was monitored by measuring the optical den-
sity at 600 nm (OD600). Upon reaching an OD600 of ~0.5, 
Ferric chloride (FeCl3·6H2O) was added (0.02  mM final 
concentration) and temperature was lowered to 18  °C. 
When the OD reached (0.8–1), IPTG was added (0.2 mM 
final concentration) to induce expression of ndmA and 
ndmD. The IPTG concentration of 0.2 mM was previously 
determined to give optimum protein expression [43]. Cells 
were harvested after (14–16)  hours of induction by cen-
trifugation at 10,000g for 20 min at 4 °C and washed twice 
in 50 mM cold potassium phosphate (KPi) buffer (pH 7.5). 
Pelleted cells (wet cells) were weighed and re-suspended in 
50 mM KPi buffer prior to activity assays.
Assays for 3MX and 1MX production
Other than where noted, reactions were carried out in 
2  mL microcentrifuge tubes with 1  mL total reaction 
volume containing an initial TP concentration of 1  mM 
and wet cell concentration of 15 mg/mL. A VWR® sym-
phony™ Incubating Microplate Shaker was used to carry 
out the reaction at 30  °C and 400  rpm. 100  µL Samples 
were taken periodically for HPLC analysis, and concentra-
tions of TP, 3MX and 1MX were calculated using appro-
priate standards. Reactions for product isolation were 
carried out in 1.3 L total volume with the same cell and TP 
concentrations as above (15 g/L and 1 mM, respectively). 
These large-scale reactions were carried out in an Excella 
E24 Incubator Shaker (Eppendorf, Hamburg, Germany) 
shaker at 30 °C and 250 rpm. After all TP was consumed, 
the post-reaction mixture was centrifuged at 10,000 x g to 
separate the supernatant (products) from the cells.
Preparatory HPLC methods and product isolation
Purification of 3MX and 1MX was carried out with pre-
paratory-scale HPLC using a Shimadzu LC-10AD HPLC 
system equipped with a photodiode array detector. A 
Hypersil BDS C18 column of 21.2 mm diameter and 25 cm 
length was used as the stationary phase. Methanol–water-
acetic acid (5:95:0.5, vol/vol/vol) was used as the mobile 
phase with an optimized flow rate of 2.5  mL/min. The 
molecules resolved by the C18 column passed through the 
photodiode array detector, in which UV–visible absorp-
tion spectra were recorded. This HPLC is equipped with 
two pumps, A and B. The isocratic method was developed 
to be programmed so that pump B provided the mobile 
phase and pump A injected 25 mL of post-reaction mix-
ture in 10  min periods. At the end of the preparative 
chromatography 900 mL 3MX solution and 700 mL 1MX 
solution were collected in two separate bottles. The solu-
tions were concentrated by vacuum drying using Buchi 
Rotovap R114. The bath temperature was 60–70  °C. Vol-
ume reduction was 200 mL for 3MX solution and 150 mL 
1MX. Both solutions were frozen to −80 °C and then were 
dried overnight in a Virtis Genesis 35EL freeze dryer (SP 
Scientific, Stone Ridge, NY) with a vacuum of 90 torr.
Analytical procedures
Identification and quantification of TP, 3MX, and 1MX 
were conducted on the same HPLC system described 
above. A Hypersil BDS C18 column (4.6 by 125  mm) 
was used as the stationary phase. The same mobile phase 
was used with a flow rate of 0.5 mL/min. Purity of 3MX 
was confirmed by high resolution LC–MS facility at the 
University of Iowa, Department of Chemistry using a 
Waters Q-TOF Premier interfaced with an Acquity UPLC 
system. The NMR results were obtained from the NMR 
facility at the Chemistry Department of the University 
of Iowa. The spectrum was recorded in DMSO-d6 with a 
Bruker DRX 500 NMR spectrometer at 300 K. The chem-
ical shifts were relative to DMSO-d6 using the standard δ 
notation in parts per million.
Additional file
Additional file 1: Table S1. Prices of various natural methylxanthines 
obtained from the Sigma–Aldrich website on 18 September, 2015. Table 
S2. Estimated copy number of ndmA and ndmD genes in strains used in 
this study. Table S3. Comparison of growth and activity of resting cell 
suspensions of strains pDdA, pDdAA, and pAD1dDD. Concentrations of 
TP, 3MX, and 1MX after 90 min are reported as means with standard devia-
tions of triplicate reactions. Table S4. Comparison of growth and activity 
of resting cell suspension of strain pDdA grown in LB and SB. Concentra-
tions of TP, 3MX, and 1MX after 2 h are reported as means with standard 
deviations of triplicate reactions. Figure S1. Maps of plasmids in strains 
used to produce 3MX from TP. ori_pBR322, pBR322 origin of replication; 
ori_P15A, P15A origin of replication; Amp-R, ampicillin resistance gene, 
Kan-R, kanamycin resistance gene, CAT, chloramphenicol resistance gene, 
ndmA, N1-demethylase gene; ndmD, N-demethylase reductase gene; 
His-ndmD, N-terminal His6-tagged N-demethylase reductase gene; T7, 
T7 promoter. Plasmids beginning with “p” use pET backbones, plasmids 
beginning with “d” use the pACYCDuet-1 plasmid backbone. Figure 
S2. SDS-PAGE analysis of ndmA and ndmD expression in metabolically 
engineered strains of E. coli. A total of 10 μg protein was loaded into each 
well. Molecular weights of markers (in kDa) are shown to the left of the 
gel. Blue arrows indicate NdmA and NdmD protein bands. Lane 1, pAD1 
soluble fraction; lane 2, pAD1 insoluble fraction; lane 3, pDdA soluble 
fraction; lane 4, pDdA insoluble fraction; lane 5, BL21(DE3) soluble fraction 
(negative control); lane 6, molecular weight standard; lane 7, pAD1DD 
soluble fraction; lane 8, pAD1DD insoluble fraction; lane 9, pDdAA soluble 
fraction; lane 10, pDdAA insoluble fraction. Figure S3. Separation of 3MX 
and 1MX by preparative chromatography. Retention times of 3MX and 
1MX are 116 and 135 min, respectively. Figure S4. NMR of 3-methylxan-
thine. (A) NMR of 3MX standard obtained from Sigma Aldrich. (B) NMR of 
biologically produced and purified 3MX sample produced in this work
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